Background: Acute amyloid leukemia (AML), an aggressive form of leukemia has been majorly treated by the anthracycline anticancer drug Doxorubicin (DOX). Yet DOX has been recorded to be cardiotoxic. Moringa oleifera (MO), a medicinal plant, has been presently exploited to test its anti-oxidative stress, anti-inflammatory, anti-apoptotic potency effect on DOX cardiotoxicity. Objective: the aim of this study was the assessment of any protective effect of MO on cardiotoxicity induced by DOX. Materials and Methods: 70 young adult male albino rats (150 – 180 gm) were allotted into seven groups (10 rats/group): normal control (given i.p. injection with normal saline); MO group (given MO extract 680 mg/day orally); DOX group (given by i.p. injection at a dose of 10mg/kg b.w.); benzene induced leukemia group BIL (induced by intravenous injection of 0.2 mL of a 1:10 diluted benzene solution every 2 days for 3 consecutive weeks); BIL+DOX group; BIL+ MO group and BIL+DOX+MO group for 4 weeks experimental duration. Results: Present results indicate a significant increase in cardiac enzyme levels CRP, CK, and LDH; a significant increase in MDA with a reduction in GSH and GPx oxidative status; a significant increase in TNF-α, NF-ΚB and MCP-1 inflammatory markers; increase in P53, caspase 3 with a decrease in Bcl2 apoptotic markers and a significant increase in cardiac ɤ-H2AX and ET-1 genes in DOX, BIL and BIL+DOX groups. All levels were ameliorated with MO therapy especially noted with the double stress of DOX+MO. Similarly, histological alterations of myocardial vacuolation, fragmentation, nuclear damage, and loss of striation after DOX, BIL, and BIL+DOX treatment were recovered following MO or DOX+MO therapy to BIL rats. Accordingly, MO has shown to be cardioprotective. Conclusion: Concurrent study suggests that MO may be considered as a potentially useful candidate in combination with Dox to limit free radical-mediated heart injury.